{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:55:53Z","timestamp":1787756153118,"version":"build-2784847793"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This meta-analysis aimed to evaluate the safety and efficacy of anti-IL-5 monoclonal antibody (anti-IL-5 mAb) as a second-line therapy for chronic rhinosinusitis with nasal polyps (CRSwNP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Four databases (PubMed, Web of Science, Embase and Cochrane Library) were searched from the establishment of the databases to September 15, 2025, for randomized controlled trials (RCTs) comparing anti-IL-5 mAb versus placebo in the treatment of CRSwNP. The primary outcome measure of this meta-analysis were nasal polyp score (NPS) and Sino-Nasal Outcome Test-22 (SNOT-22) score. Secondary outcome measures included nasal blockage score (NBS), loss of smell score (LSS), Lund-Mackay score (LMS), University of Pennsylvania Smell Identification Test (UPSIT) score, nasal overall visual analog scale(VAS) score, nasal composite visual analog scale(VAS) score, number of first-time NP surgery patients and number of systemic corticosteroids (\u22651 course) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Totally 10 RCTs were included for meta-analysis. Compared with placebo, anti-IL-5 mAb provided a significantly lower NPS (WMD = -0.58, 95%CI: -0.70 ~ -0.46, P &amp;lt; 0.00001, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a083%), SNOT-22 score (WMD: -9.57, 95% CI: -11.03 ~ -8.11, P\u00a0&amp;lt; 0.00001, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a080%), NBS (SMD: -1.75; 95% CI: -3.13 ~ -0.36, P\u00a0=\u00a00.01, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a099%), LSS (SMD: -1.68; 95% CI: -3.13 ~ -0.24, P\u00a0=\u00a00.02, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a099%), LMS (WMD: -2.00; 95% CI: -2.65 ~ -1.34, P &amp;lt; 0.00001, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a097%), nasal overall VAS score (WMD: -1.54, 95% CI: -1.64 ~ -1.43, P &amp;lt; 0.00001, I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%), nasal composite VAS score (WMD: -1.28, 95% CI:\u00a0-1.66 ~ -0.19, P &amp;lt; 0.00001, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%), number of first-time NP surgery patients (RR: 0.64, 95% CI: 0.41 ~ 1.00, P\u00a0=\u00a00.05, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a069%) and number of systemic corticosteroids (\u22651 course) patients (RR: 0.73, 95% CI: 0.62 ~ 0.86, P\u00a0=\u00a00.0002, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%), while significantly improved UPSIT (WMD: 2.09, 95% CI: 0.42 ~ 3.77, P\u00a0=\u00a00.01, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This results confirmed that anti-IL-5 mAb therapy was safe and effective for CRSwNP and can serve as a second-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251170717.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1746573","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:26:27Z","timestamp":1774848387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Huixiu","family":"Liao","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Rongshui Miao Autonomous County People\u2019s Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Luo","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyu","family":"Qin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Quan","sequence":"additional","affiliation":[{"name":"School of Economics and Management, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Liang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongying","family":"Qin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87760","article-title":"Determination of sensitivity and specificity of diagnostic nasal endoscopy compared to computed tomography scan of nasal and paranasal sinuses among patients suffering from chronic rhinosinusitis","volume":"17","author":"Singh","year":"2025","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe--an underestimated disease. A GA\u00b2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3205\/cto000126","article-title":"Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden","volume":"14","author":"Beule","year":"2015","journal-title":"GMS Curr Topics Otorhinolaryngol Head Neck Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00725.x","article-title":"Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments","volume":"60","author":"Alobid","year":"2005","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4193\/rhino11.101","article-title":"A multi-centre study on quality of life and absenteeism in patients with CRS referred for endoscopic surgery","volume":"49","author":"Sahlstrand-Johnson","year":"2011","journal-title":"Rhinology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2500\/ajra.2009.23.3355","article-title":"Contemporary assessment of the disease burden of sinusitis","volume":"1","author":"Bhattacharyya","year":"2010","journal-title":"Allergy Rhinol (Providence RI)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.07.025","article-title":"Diagnosis and management of rhinosinusitis: a practice parameter update","volume":"113","author":"Peters","year":"2014","journal-title":"Ann Allergy Asthma Immunol: Off Publ Am Coll Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.124.5.513","article-title":"Effect of fluticasone in severe polyposis","volume":"124","author":"Lund","year":"1998","journal-title":"Arch Otolaryngology--Head Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-16724-4_15","article-title":"Oral corticosteroids in the management of adult chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations","volume":"3","author":"Poetker","year":"2013","journal-title":"Int Forum Allergy Rhinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4193\/rhin23.415","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051025","article-title":"Biologics reduce symptoms of alcohol intolerance better than aspirin desensitization in patients with N-ERD and nasal polyps","volume":"12","author":"Foerster-Ruhrmann","year":"2024","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4193\/rhin24.209","article-title":"Real-world treatment of chronic rhinosinusitis with dupilumab and omalizumab: results from the Korean National Health Insurance Service database","volume":"63","author":"Han","year":"2025","journal-title":"Rhinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-025-09619-y","article-title":"Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience","volume":"282","author":"Loperfido","year":"2025","journal-title":"Eur Arch Oto-Rhino-Laryngol: Off J Eur Fed Oto-Rhino-Laryngol Societies (EUFOS): Affiliated German Soc For Oto-Rhino-Laryngol - Head Neck Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/1750743x.2025.2567844","article-title":"Evaluating the efficacy and safety of tezepelumab in the treatment of chronic rhinosinusitis with nasal polyps","volume":"17","author":"Priessnitz","year":"2025","journal-title":"Immunotherapy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040522","article-title":"Sequential biotherapy targeting IL-5 and IL-4\/13 in patients with eosinophilic asthma with sinusitis and otitis media","volume":"12","author":"Chikumoto","year":"2022","journal-title":"Biomolecules"},{"key":"B19","article-title":"Eosinophil differentiation factor (interleukin-5)","volume":"49","author":"Sanderson","year":"1990","journal-title":"Immunol Ser"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.2.341","article-title":"Molecular cloning and expression of the human interleukin 5 receptor","volume":"175","author":"Murata","year":"1992","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy: J Br Soc For Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4193\/rhin24.156","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda","year":"2024","journal-title":"Rhinology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet (London England)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-019-05752-7","article-title":"A comparison of international clinical practice guidelines on adult chronic rhinosinusitis shows considerable variability of recommendations for diagnosis and treatment","volume":"277","author":"Kaper","year":"2020","journal-title":"Eur Arch Oto-Rhino-Laryngol: Off J Eur Fed Oto-Rhino-Laryngol Societies (EUFOS): Affiliated German Soc For Oto-Rhino-Laryngol - Head Neck Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29766","article-title":"Development of sinonasal outcome test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps","volume":"132","author":"Khan","year":"2022","journal-title":"Laryngoscope"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09340-x","article-title":"Screening performance of abbreviated versions of the UPSIT smell test","volume":"266","author":"Joseph","year":"2019","journal-title":"J Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.12.022","article-title":"Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis","volume":"14","author":"Liu","year":"2026","journal-title":"J Cyst Fibros"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02037-0","article-title":"Anti-IL-5 pathway agents in eosinophilic-associated disorders across the lifespan","volume":"84","author":"Lombardi","year":"2024","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cell.2016.04.020","article-title":"Humanized anti-IL-5 antibody therapy","volume":"165","author":"Rothenberg","year":"2016","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19136","article-title":"Managing adult asthma: the 2019 GINA guidelines","volume":"87","author":"Mauer","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2021.12.427","article-title":"Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma","volume":"17","author":"Gurnell","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000521859","article-title":"Efficacy and safety of anti-interleukin-5 therapies in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomized controlled trials","volume":"183","author":"Wang","year":"2022","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1746573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:26:29Z","timestamp":1774848389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1746573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1746573"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1746573","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"article-number":"1746573"}}